A carregar...
Catumaxomab: Clinical development and future directions
Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the european Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites. The marketing authorization holder Fresenius Biotech GmbH developed catumaxomab (Removab(®)) together with its partner T...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2840231/ https://ncbi.nlm.nih.gov/pubmed/20190561 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|